Loading stock data…
MBRX
$2.51-0.05 (-1.95%)
Market ClosedLast close May 1
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Moleculin Biotech, Inc. in the Healthcare sector is trading at $2.51. The stock is currently near its 52-week low of $1.79, remaining 68.2% below its 200-day moving average. Technical signals show neutral RSI of 36 and bullish MACD crossover, explaining why MBRX maintains its current current market pressure. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 36) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.51
Potential Upside
5%
Whystock Fair Value$2.64
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$21.00+736.7%
Range$10.00 – $31.00
Fundamentals
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.67
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-223.64%
Volume
Today's trading volume
24,939
Recent News
Moleculin Biotech announces issuance of Canadian patent covering Annamycin
Moleculin Biotech (MBRX) announced that the Canadian Intellectual Property Office, CIPO, has issued a notice of allowance for Patent Application No. 3,142,510 titled, “PREPARATION OF PRELIPOSOMAL ANNAMYCIN LYOPHILIZATE.” A patent from the application is expected to be issued in the coming months. When issued, the patent claims will cover methods of making a preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term currently extending until June 2040, su
Moleculin Biotech (MBRX) Upgraded to Buy: Here's What You Should Know
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Several Insiders Invested In Moleculin Biotech Flagging Positive News
When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...
Moleculin Biotech prices 16.08M shares at 37c in public offering
Moleculin Biotech (MBRX) announced the pricing of a public offering consisting of 16,080,000 shares of common stock and Series E warrants to purchase up to 48,240,000 shares of its common stock, at a combined public offering price per share of common stock and accompanying Series E warrants of 37c. The Series E warrants will have an exercise price of 37c per share, are exercisable upon stockholder approval, and will expire five years following the initial exercise date. The offering is expected
Moleculin Biotech announces ‘What This Means’ virtual investor segment
Moleculin Biotech (MBRX) participated in a Virtual Investor “What This Means” segment. For the segment, Brian Andrew Van Tine, MD, PhD, Professor of Medicine, Washington University School of Medicine, discussed the Company’s recently announced positive topline efficacy results from its completed U.S. Phase 1B/2 clinical trial evaluating Annamycin for the treatment of Soft Tissue Sarcoma Lung Metastases. The MB-107 trial was a multi-center, open-label, single-arm monotherapy study that in Phase 1